Sanofi's Dupixent Gets FDA Priority Review for COPD
Ticker: SNYNF · Form: 6-K · Filed: Jun 11, 2024 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: FDA, priority-review, drug-approval, respiratory
TL;DR
FDA priority review for Dupixent in COPD - decision by Aug 20, 2024. Big potential market expansion for Sanofi.
AI Summary
Sanofi announced on May 31, 2024, that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental New Drug Application (sNDA) for Dupixent (dupilumab) to treat adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who have evidence of type 2 inflammation. The FDA is expected to make a decision by August 20, 2024. This filing incorporates press releases from May and June 2024.
Why It Matters
This FDA priority review could expand Dupixent's market to a significant COPD patient population, potentially boosting Sanofi's revenue if approved.
Risk Assessment
Risk Level: medium — The outcome of the FDA review for Dupixent's expanded use in COPD is uncertain, posing a risk to future revenue projections.
Key Players & Entities
- Sanofi (company) — Registrant
- Dupixent (company) — Drug
- dupilumab (company) — Drug active ingredient
- U.S. Food and Drug Administration (FDA) (company) — Regulatory body
- August 20, 2024 (date) — FDA decision date
- May 31, 2024 (date) — Press release date
FAQ
What is the specific indication Sanofi is seeking for Dupixent?
Sanofi is seeking approval for Dupixent to treat adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who have evidence of type 2 inflammation.
What is the expected decision date from the FDA regarding Dupixent for COPD?
The FDA is expected to make a decision by August 20, 2024.
What type of review is the FDA conducting for Dupixent's sNDA?
The FDA is conducting a priority review of the supplemental New Drug Application (sNDA) for Dupixent.
Which press releases are incorporated into this 6-K filing?
Press releases published in May and June 2024, specifically Exhibit 99.1 dated May 31, 2024, are incorporated by reference.
What is Sanofi's principal executive office address?
Sanofi's principal executive offices are located at 46, avenue de la Grande Armée, 75017 Paris, FRANCE.
Filing Stats: 260 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2024-06-11 13:54:55
Filing Documents
- d845693d6k.htm (6-K) — 11KB
- d845693dex991.htm (EX-99.1) — 31KB
- d845693dex992.htm (EX-99.2) — 32KB
- d845693dex993.htm (EX-99.3) — 15KB
- d845693dex994.htm (EX-99.4) — 34KB
- g845693g0527225640753.jpg (GRAPHIC) — 3KB
- g845693g06x08.gif (GRAPHIC) — 1KB
- g845693sp4.jpg (GRAPHIC) — 8KB
- g845693sp4g04.jpg (GRAPHIC) — 5KB
- 0001193125-24-158972.txt ( ) — 146KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: June 11, 2024 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3